Dual-Functioning Metal-Organic Frameworks: Methotrexate-Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers

Basit Öğe Kaydı
dc.contributor.authorKaraca, Burcu
dc.contributor.authorSakarya, Deniz
dc.contributor.authorSiyah, Pınar
dc.contributor.authorŞenışık, Ahmet Murat
dc.contributor.authorKaptan, Yasemin
dc.contributor.authorÇavuşoğlu, Ferda C.
dc.contributor.authorMansuroğlu, Demet S.
dc.contributor.authorÖztürk, Sadullah
dc.contributor.authorBayazıt, Şahika S.
dc.contributor.authorBarlas, Fırat
dc.date.accessioned2025-06-02T06:02:15Z
dc.date.available2025-06-02T06:02:15Z
dc.date.issued2025
dc.departmentMeslek Yüksekokulları, Sağlık Hizmetleri Meslek Yüksekokulu, Radyoterapi Programı
dc.description.abstractCancer remains a critical global health challenge, necessitating advanced drug delivery systems through innovations in materials science and nanotechnology. This study evaluates gadolinium metal-organic frameworks (Gd-MOFs) as potential drug delivery systems for anticancer therapy, particularly when combined with radiotherapy. Gd-MOFs were synthesized using terephthalic acid and gadolinium (III) chloride hexahydrate and then loaded with methotrexate (MTX). Characterization via fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), magnetic resonance imaging (MRI), and X-ray diffraction (XRD) confirmed their correct structure and stability. Effective MTX loading and controlled release were demonstrated. Anticancer effects were assessed on human healthy bronchial epithelial cells (BEAS-2B) and human lung cancer cells (A549) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay under in vitro radiation therapy. MTX/Gd-MOF combined with radiotherapy showed a greater reduction in cancer cell viability (41.89% ± 2.75 for A549) compared to healthy cells (56.80% ± 1.97 for BEAS-2B), indicating selective cytotoxicity. These findings highlight the potential of Gd-MOFs not only as drug delivery vehicles but also as radiosensitizers, enhancing radiotherapy efficacy and offering promising evidence for their use in combinatory cancer therapies to improve treatment outcomes.
dc.identifier.citationKaraca, B., Sakarya, D., Siyah, P., Senisik, A. M., Kaptan, Y., Çavusoglu, F. C., ... & Barlas, F. B. (2025). Dual‐Functioning Metal‐Organic Frameworks: Methotrexate‐Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers. Chemistry–A European Journal, 31(24), e202404106.
dc.identifier.doi10.1002/chem.202404106
dc.identifier.issn0947-6539
dc.identifier.issn1521-3765
dc.identifier.issue24
dc.identifier.pmid40079794
dc.identifier.scopus2-s2.0-105003823363
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5762
dc.identifier.volume31
dc.identifier.wosWOS:001479486400014
dc.identifier.wosqualityQ2
dc.indekslendigikaynakPubMed
dc.institutionauthorŞenışık, Ahmet Murat
dc.language.isoen
dc.relation.ispartofChemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGd‐MOF
dc.subjectMRI
dc.subjectcontrolled drug release
dc.subjectmethotrexate
dc.subjectradiotherapy
dc.titleDual-Functioning Metal-Organic Frameworks: Methotrexate-Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
2.2 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Sağlık Hizmetleri Meslek Yüksekokulu Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu